Abstract
Inhibition of the renin–angiotensin–aldosterone system (RAAS) is a successful therapy for hypertension, heart failure, and renal insufficiency. Overdosing of RAAS inhibitors is occasionally observed when several agents are used together, and can cause adverse events such as hypotension, hyperkalaemia, and renal failure. We advocate optimal, rather than complete, RAAS blockade.
MeSH terms
-
Angiotensin II Type 1 Receptor Blockers / adverse effects
-
Angiotensin II Type 1 Receptor Blockers / therapeutic use*
-
Angiotensin-Converting Enzyme Inhibitors / adverse effects
-
Angiotensin-Converting Enzyme Inhibitors / therapeutic use*
-
Antihypertensive Agents / adverse effects
-
Antihypertensive Agents / therapeutic use*
-
Blood Pressure / drug effects
-
Drug Therapy, Combination
-
Heart Failure / drug therapy*
-
Heart Failure / physiopathology
-
Humans
-
Hypertension / drug therapy*
-
Hypertension / physiopathology
-
Hypokalemia / chemically induced
-
Hypotension / chemically induced
-
Hypotension / physiopathology
-
Meta-Analysis as Topic
-
Renal Insufficiency / chemically induced
-
Renal Insufficiency / physiopathology
-
Renin / antagonists & inhibitors*
-
Renin / metabolism
-
Renin-Angiotensin System / drug effects*
-
Treatment Outcome
Substances
-
Angiotensin II Type 1 Receptor Blockers
-
Angiotensin-Converting Enzyme Inhibitors
-
Antihypertensive Agents
-
Renin